Compare Stocks: FBLG, ATYR, CELU, and CNTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$0.38 -1.3%	$0.50	$0.38 ▼ $1.12	$38.18M	0.53	713,152 shs	942,418 shs
CELU Celularity	$1.29 +4.0%	$1.00	$0.56 ▼ $2.55	$35.89M	0.79	12.25 million shs	180,906 shs
CNTX Context Therapeutics	$0.38 +4.0%	$0.50	$0.34 ▼ $3.62	$33.48M	1.69	1.83 million shs	2.13 million shs
FBLG FibroBiologics	$1.43 -0.7%	$1.17	$0.62 ▼ $12.40	$9.59M	1.65	323,170 shs	117,073 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	-1.31%	-16.50%	-25.98%	-14.74%	-64.44%
CELU Celularity	+4.03%	-10.42%	+85.34%	+71.47%	-40.00%
CNTX Context Therapeutics	+4.01%	+2.43%	-28.53%	-40.02%	-55.30%
FBLG FibroBiologics	-0.69%	-18.75%	+40.20%	+85.67%	-86.50%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$0.38 -1.3%	$0.50	$0.38 ▼ $1.12	$38.18M	0.53	713,152 shs	942,418 shs
CELU Celularity	$1.29 +4.0%	$1.00	$0.56 ▼ $2.55	$35.89M	0.79	12.25 million shs	180,906 shs
CNTX Context Therapeutics	$0.38 +4.0%	$0.50	$0.34 ▼ $3.62	$33.48M	1.69	1.83 million shs	2.13 million shs
FBLG FibroBiologics	$1.43 -0.7%	$1.17	$0.62 ▼ $12.40	$9.59M	1.65	323,170 shs	117,073 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	-1.31%	-16.50%	-25.98%	-14.74%	-64.44%
CELU Celularity	+4.03%	-10.42%	+85.34%	+71.47%	-40.00%
CNTX Context Therapeutics	+4.01%	+2.43%	-28.53%	-40.02%	-55.30%
FBLG FibroBiologics	-0.69%	-18.75%	+40.20%	+85.67%	-86.50%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR aTyr Pharma	2.67	Moderate Buy	N/A	N/A
CELU Celularity	1.00	Sell	N/A	N/A
CNTX Context Therapeutics	2.70	Moderate Buy	$6.17	1,527.09% Upside
FBLG FibroBiologics	1.80	Reduce	$73.00	5,004.90% Upside

Current Analyst Ratings Breakdown

Latest FBLG, ATYR, CELU, and CNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	FBLG FibroBiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
9/3/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	CELU Celularity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	FBLG FibroBiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/13/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/6/2026	CNTX Context Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/6/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/6/2026	CNTX Context Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/5/2026	CELU Celularity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/4/2026	FBLG FibroBiologics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00 ➝ $6.00

(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR aTyr Pharma	$190K	198.30	N/A	N/A	$0.69 per share	0.56
CELU Celularity	$26.55M	1.41	N/A	N/A	($1.32) per share	-0.98
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$0.66 per share	N/A
FBLG FibroBiologics	N/A	N/A	N/A	N/A	$1.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR aTyr Pharma	-$74.12M	-$0.62	N/A	N/A	N/A	N/A	-95.89%	-69.67%	11/5/2026 (Estimated)
CELU Celularity	-$91.72M	-$3.33	N/A	N/A	N/A	-345.45%	N/A	-77.94%	11/13/2026 (Estimated)
CNTX Context Therapeutics	-$36.12M	-$0.48	N/A	N/A	N/A	N/A	-82.06%	-72.74%	11/4/2026 (Estimated)
FBLG FibroBiologics	-$18.65M	-$5.19	N/A	N/A	N/A	N/A	-536.78%	-225.12%	10/30/2026 (Estimated)

Latest FBLG, ATYR, CELU, and CNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q2 2026	ATYR aTyr Pharma	-$0.1214	-$0.11	+$0.0114	-$0.11	N/A	$189.56 million
8/5/2026	Q2 2026	CNTX Context Therapeutics	-$0.0921	-$0.15	-$0.0579	-$0.15	N/A	N/A
7/31/2026	Q2 2026	FBLG FibroBiologics	-$0.93	-$0.66	+$0.27	-$0.66	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
CELU Celularity	N/A	N/A	N/A	N/A	N/A
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
FBLG FibroBiologics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR aTyr Pharma	N/A	5.12	5.12
CELU Celularity	N/A	0.15	0.15
CNTX Context Therapeutics	N/A	5.81	5.81
FBLG FibroBiologics	N/A	2.64	2.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR aTyr Pharma	61.72%
CELU Celularity	19.02%
CNTX Context Therapeutics	14.03%
FBLG FibroBiologics	N/A

Insider Ownership

Company	Insider Ownership
ATYR aTyr Pharma	5.75%
CELU Celularity	17.30%
CNTX Context Therapeutics	4.80%
FBLG FibroBiologics	7.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR aTyr Pharma	53	98.09 million	92.45 million	Optionable
CELU Celularity	220	28.95 million	23.94 million	Optionable
CNTX Context Therapeutics	7	91.88 million	87.47 million	Not Optionable
FBLG FibroBiologics	10	6.66 million	6.17 million	N/A

FBLG, ATYR, CELU, and CNTX Headlines

Recent News About These Companies

FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer

34 minutes ago | prnewswire.com

FibroBiologics Inc. (NASDAQ:FBLG) Short Interest Up 192.0% in August

September 13, 2026 | americanbankingnews.com

FibroBiologics: Advancing Fibroblast Cell Therapy Platform

September 8, 2026 | usatoday.com

Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications

September 8, 2026 | finance.yahoo.com

FibroBiologics Secures U.S. Patent For Fibroblast-Based Wound Healing Therapy; Stock Down

September 3, 2026 | rttnews.com

FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing

September 3, 2026 | prnewswire.com

FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media

September 1, 2026 | prnewswire.com

FibroBiologics, Inc. livre son troisième lot de CYWC628 pour l'essai clinique de phase 1/2 sur l'ulcère du pied diabétique

August 29, 2026 | zonebourse.comZ

FibroBiologics advances diabetic ulcer trial with new drug shipment to Australia

August 27, 2026 | proactiveinvestors.co.uk

FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

August 27, 2026 | prnewswire.com

FibroBiologics Regains Compliance with Nasdaq Trading Rules

August 26, 2026 | prnewswire.com

FibroBiologics Appoints Leigh Steinberg to Board of Directors

August 24, 2026 | prnewswire.com

FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease

August 20, 2026 | prnewswire.com

FibroBiologics Says Preclinical Data Shapes Design of Further Studies for Degenerative Joint Treatment

August 18, 2026 | benzinga.com

FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints

August 18, 2026 | prnewswire.com

FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets

August 11, 2026 | prnewswire.com

FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage

August 5, 2026 | prnewswire.com

Fibrobiologics (FBLG) Stock Forecast & Price Target

August 4, 2026 | investing.com

FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate

July 31, 2026 | prnewswire.com

FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors

July 9, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG, ATYR, CELU, and CNTX Company Descriptions

aTyr Pharma NASDAQ:ATYR

$0.38 -0.01 (-1.31%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$0.39 +0.01 (+1.80%)

As of 08:59 AM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Celularity NASDAQ:CELU

$1.29 +0.05 (+4.03%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$1.30 +0.01 (+0.78%)

As of 09:02 AM Eastern

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Context Therapeutics NASDAQ:CNTX

$0.38 +0.01 (+4.01%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$0.38 0.00 (-1.06%)

As of 08:58 AM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

FibroBiologics NASDAQ:FBLG

$1.43 -0.01 (-0.69%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$1.50 +0.07 (+4.55%)

As of 08:45 AM Eastern

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FBLG, ATYR, CELU, and CNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FBLG, ATYR, CELU, and CNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FBLG, ATYR, CELU, and CNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG, ATYR, CELU, and CNTX Company Descriptions

aTyr Pharma NASDAQ:ATYR

Celularity NASDAQ:CELU

Context Therapeutics NASDAQ:CNTX

FibroBiologics NASDAQ:FBLG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FBLG, ATYR, CELU, and CNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FBLG, ATYR, CELU, and CNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FBLG, ATYR, CELU, and CNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG, ATYR, CELU, and CNTX Company Descriptions

aTyr Pharma NASDAQ:ATYR

Celularity NASDAQ:CELU

Context Therapeutics NASDAQ:CNTX

FibroBiologics NASDAQ:FBLG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools